tirzepatide and semaglutide therapeutic modality vs 2026: 22% vs 15% Weight Loss Guide tirzepatide semaglutide therapeutic modality Semaglutide

The exact reason is unknown, and researchers need to conduct more studies

: CLA ,

They are not intended to represent clinical evidence in humans, and Epithalon has not been approved by the FDA, EMA, or any other regulatory authority for any indication

A 2021 peer-reviewed review of NNMT in obesity and type 2 diabetes states explicitly that 'clinical trials targeting NNMT have not been reported' meaning every quantitative efficacy figure available for this compound comes from mice, and there is currently zero published human efficacy data

It is strictly for research purposes only, and human safety is not established

& Lodders, K